Please login (Members) to view content or
(Nonmembers) this article.
No votes yet

Understanding Novel Therapeutic Agents for Multiple Myeloma

Joseph D. Tariman
CJON 2003, 7(5), 521-528 DOI: 10.1188/03.CJON.521-528

Multiple myeloma, a B cell malignancy of the plasma cells, remains incurable. Advances in high-dose chemotherapy and stem cell transplantation have improved overall survival and event-free disease periods, but relapses are inevitable. New therapeutic agents have shown promising clinical use in patients with relapsed or refractory multiple myeloma. This article discusses the therapeutic applications of these novel agents with a focus on immunomodulatory drugs, proteasome inhibitors, and arsenic compounds.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or